NCT03865394View on ClinicalTrials.gov

Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

September 30, 2021

Conditions
Diabetic Foot Ulcer
Interventions
BIOLOGICAL

Application of allogeneic ADSC stem cells in fibrin gel

Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - single dose will be administered followed by weekly wound control.

PROCEDURE

Standard care in diabetic foot ulcer

Chronic wounds in diabetic foot ulcer will be covered with fibrin gel followed by weekly wound control.

Trial Locations (1)

Unknown

Medical University of Warsaw, Department of Diabetology and Internal Diseases, Warsaw

All Listed Sponsors
collaborator

Polish Stem Cells Bank S.A.

UNKNOWN

lead

Medical University of Warsaw

OTHER

NCT03865394 - Treatment of Chronic Wounds in Diabetic Foot Syndrome With Allogeneic Adipose Derived Mesenchymal Stem Cells | Biotech Hunter | Biotech Hunter